News
Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...
Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
StockStory.org on MSN16h
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Moderna 57, a new Italian restaurant next to the Syosset train station, offers over 100 dishes to diners. The owner, Paul ...
Enphase Energy (ENPH) retained its spot as the most shorted S&P 500 (SP500) stock as a percentage of float in June, followed ...
This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...
Sioux City put a damper on Cleburne’s series-winning streak as the Railroaders dropped all three games to the Explorers over ...
The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Explore last week's key healthcare market trends, top gainers & losers, major deals, Trump's tariff plans, FDA approvals, and significant legal updates.
The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results